Search
Spotlight
CME Opportunities
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Global Perspectives on Advanced Breast Cancer Management
EP. 1: CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer
October 5th 2017
EP. 2: Biomarkers for CDK4/6 Inhibitors in HR+ mBC
October 5th 2017
EP. 3: Efficacy of CDK4/6 Inhibitors in HR+ mBC
October 5th 2017
EP. 4: Differences Among CDK4/6 Inhibitors in HR+ mBC
October 5th 2017
EP. 5: Abemaciclib With Hormone Therapy for HR+ mBC
October 5th 2017
EP. 6: Fulvestrant in the Era of CDK4/6 Inhibitors for HR+ mBC
October 5th 2017
EP. 7: Neoadjuvant PI3 Kinase Inhibitors for HR+ Breast Cancer
October 5th 2017
EP. 8: Post-Adjuvant Therapy for HER2+ Breast Cancer
October 5th 2017
EP. 9: Adjuvant Therapy for ER+/HER2+ Breast Cancer
October 5th 2017
EP. 10: Breast Cancer: Dual HER2-Targeted Adjuvant Therapy
October 5th 2017
EP. 11: HER2+ Breast Cancer: Neratinib Patient Selection
October 5th 2017
EP. 12: PARP Inhibitors for BRCA-Associated TNBC
October 5th 2017
EP. 13: Role of Neoadjuvant Platinum-Based Therapy for TNBC
October 5th 2017
EP. 14: AR-Targeted Therapy and Immunotherapy for TNBC
October 5th 2017
EP. 15: The Path Forward in Breast Cancer Research
October 5th 2017
x